Drug Type Small molecule drug |
Synonyms Remetinostat (USAN/INN), SHAPE, 37NT056AT4 + [2] |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H21NO6 |
InChIKeyXDZAHHULFQIBFE-UHFFFAOYSA-N |
CAS Registry946150-57-8 |
Start Date12 Dec 2019 |
Sponsor / Collaborator |
Start Date01 Oct 2019 |
Sponsor / Collaborator- |
Start Date07 Jul 2018 |
Sponsor / Collaborator [+2] |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10977 | Remetinostat | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Squamous Cell Carcinoma | Phase 2 | US | 09 Nov 2019 | |
Basal Cell Carcinoma | Phase 2 | US | 07 Jul 2018 | |
Basal Cell Carcinoma | Phase 2 | US | 07 Jul 2018 | |
Alopecia Areata | Phase 2 | - | 01 Feb 2017 | |
Cutaneous T-Cell Lymphoma | Phase 2 | US | 01 Nov 2014 | |
Plaque psoriasis | Phase 1 | AU | 01 Sep 2012 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 25 | gcoifsgryo(hqychcokmb) = iotuihxyns bflqlvnanp (bexnewhhjm ) View more | Positive | 01 Sep 2021 | |||
Phase 2 | 4 | ldsobzabze(oumnbswelm) = ukxnbmiyvt itqtaagoow (ftajtrncav, roetuyggwz - ctakwxyrhu) View more | - | 20 May 2021 | |||
Phase 2 | 30 | hlkjgcuqbq(gkjmmsalur) = afqnfgrpsc jidheifqhh (elvqrimfhk, wxadazisfd - ytkjpmdpee) View more | - | 05 Jan 2021 | |||
NCT01433731 (ASCO2014) Manual | Phase 1 | 18 | cihzplavxz(weujvmrudm) = mxsgnolwup apjbzeqsgj (ikjsvvguew ) View more | Positive | 20 May 2014 | ||
placebo | cihzplavxz(weujvmrudm) = yewxogtnao apjbzeqsgj (ikjsvvguew ) View more |